Prelude Therapeutics (NASDAQ:PRLD) is a biotechnology company dedicated to advancing innovative treatments in oncology and rare diseases. With a keen focus on drug discovery and development, Prelude is working diligently to bring novel cancer therapies from the laboratory to clinical trials, aiming to address unmet medical needs. Their pipeline includes a range of small-molecule therapeutics designed to target key signaling pathways in cancer cells, showcasing their commitment to transforming the landscape of cancer treatment. Central to the company's objectives is the pursuit of scientific breakthroughs that can lead to life-changing treatments for patients battling cancer and other serious diseases.